Moleculin Biotech, Inc. — Form 8-K Summary
Reporting date: September 29, 2026. This is a current report about a clinical-trial milestone, not a periodic financial report.
Business context and event
Moleculin Biotech announced that it completed and closed enrollment in Part A of its pivotal Phase 2/3 MIRACLE trial. The trial evaluates Annamycin in combination with cytarabine (AnnAraC) in adults with relapsed or refractory acute myeloid leukemia (R/R AML).
- The company reported 89 subjects enrolled and two additional subjects in screening.
- It said a comprehensive Part A data readout remained on track for the first quarter of 2027.
Financial and operating metrics
The filing provides no revenue, profit or loss, cash-flow, margin, debt, liquidity, or other financial metrics. It does not provide trial results or efficacy and safety data.
Changes, outlook, and risks
The reported change is that Part A enrollment has closed. The first-quarter 2027 data readout is a company-stated plan, not a reported result. The filing gives no additional guidance, financial outlook, or detailed risk or contingency discussion.
Important facts to verify
- Whether the two subjects in screening were ultimately enrolled; the release says enrollment closed at 89 subjects “or potentially more,” leaving the final count unclear.
- The timing and contents of the planned first-quarter 2027 data readout.
- The filing references Exhibits 99.1 and 99.2, including a press release and abstract, but the exhibit list shown identifies 99.1 and 104 only; verify the filed exhibits for the abstract.